239 related articles for article (PubMed ID: 16187646)
1. The drug add-on component--have all provider types seen budget neutrality?
Mentz K
Nephrol News Issues; 2005 Sep; 19(10):42-4. PubMed ID: 16187646
[No Abstract] [Full Text] [Related]
2. Conditions for coverage fail to relieve administrative burden.
Wish D
Nephrol News Issues; 2005 Sep; 19(10):46-7, 51. PubMed ID: 16187648
[No Abstract] [Full Text] [Related]
3. Futuristic plans for ESRD--a new bundled payment system.
Michael M
Nephrol News Issues; 2005 Sep; 19(10):52, 54. PubMed ID: 16187649
[No Abstract] [Full Text] [Related]
4. The 2011 ESRD prospective payment system: welcome to the bundle.
Weiner DE
Am J Kidney Dis; 2011 Apr; 57(4):539-41. PubMed ID: 21333431
[No Abstract] [Full Text] [Related]
5. The 2011 ESRD prospective payment system: an uncontrolled experiment.
Winkelmayer WC; Chertow GM
Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428
[No Abstract] [Full Text] [Related]
6. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
Bhat P; Bhat JG
Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
[No Abstract] [Full Text] [Related]
7. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
Nissenson AR; Mayne TJ; Krishnan M
Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
[No Abstract] [Full Text] [Related]
8. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization.
Lacson E; Hakim RM
Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423
[No Abstract] [Full Text] [Related]
9. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
10. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization.
Johnson DS; Meyer KB; Johnson HK
Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427
[No Abstract] [Full Text] [Related]
11. Who should be paying for vitamin D analogues--Medicare or the patients?
Grotegut J
Nephrol Nurs J; 2006; 33(3):345-6. PubMed ID: 16912996
[No Abstract] [Full Text] [Related]
12. Impact of HCFA's revised billing instructions for kinetic modeling and recirculation tests.
Rosenthal AF; Mahlke KF
Nephrol News Issues; 1998 Feb; 12(2):12. PubMed ID: 9526364
[No Abstract] [Full Text] [Related]
13. Who should be paying for vitamin D analogues--Medicare or the patients?
Hall G
Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205
[No Abstract] [Full Text] [Related]
14. Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.
Cellini GL
Nephrol News Issues; 2016 Mar; 30(3):26-8, 30-3. PubMed ID: 27169216
[No Abstract] [Full Text] [Related]
15. How dialysis is paid for: what the dialysis medical director should know, and why.
Deoreo PB
Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259
[TBL] [Abstract][Full Text] [Related]
16. Adapting to changes in Medicare cost report requirements.
Rossi T
Nephrol News Issues; 2005 Sep; 19(10):36-9. PubMed ID: 16187645
[No Abstract] [Full Text] [Related]
17. Case-mix adjusted composite rate--did Medicare get it right?
Messana A
Nephrol News Issues; 2005 Sep; 19(10):44. PubMed ID: 16187647
[No Abstract] [Full Text] [Related]
18. The cost of clinical dialysis--a historical perspective.
Attrill E; Johnson HK
Semin Nephrol; 2000 Nov; 20(6):523-5. PubMed ID: 11111853
[No Abstract] [Full Text] [Related]
19. Medicare ESRD prospective payment system: weighing the evidence.
Himmelfarb J; Chertow GM
J Am Soc Nephrol; 2005 May; 16(5):1164-5. PubMed ID: 15829705
[No Abstract] [Full Text] [Related]
20. Is it time for Medicare to provide reimbursement for daily hemodialysis?
Newmann JM
Nephrol News Issues; 2001 Apr; 15(5):57-9. PubMed ID: 12108965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
